Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Day One Biopharmaceuticals Days Sales Outstanding Chart
DAWN vs TYRA, DFTX, MLYS: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Day One Biopharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Day One Biopharmaceuticals Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Day One Biopharmaceuticals's Days Sales Outstanding falls into.
Day One Biopharmaceuticals Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Day One Biopharmaceuticals (DAWN) has a Days Sales Outstanding of 36.89 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Day One Biopharmaceuticals and its competitors. This is 14% below median its historical median of 42.73. Over the past decade, Day One Biopharmaceuticals' Days Sales Outstanding has ranged from 38.61 to 46.85.
Is Day One Biopharmaceuticals' Days Sales Outstanding too high?
Day One Biopharmaceuticals' current Days Sales Outstanding of 36.89 is 14% below median its 10-year median of 42.73. Over the past 10 years, this metric has ranged from a low of 38.61 to a high of 46.85. The Biotechnology industry median Days Sales Outstanding is 68.94. Day One Biopharmaceuticals' value of 36.89 is 46.5% below this industry median. Overall, Day One Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Day One Biopharmaceuticals' Days Sales Outstanding compare to TYRA and DFTX?
Day One Biopharmaceuticals' Days Sales Outstanding of 36.89 can be compared against companies in the Biotechnology industry. The industry median Days Sales Outstanding is 68.94. Day One Biopharmaceuticals' value of 36.89 is 46.5% below this benchmark. Historically, Day One Biopharmaceuticals' own Days Sales Outstanding has ranged from 38.61 to 46.85 over the past decade. While the company's 10-year median is 42.73 vs. the industry median of 68.94, Day One Biopharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Day One Biopharmaceuticals's current Days Sales Outstanding of 36.89 is 46.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Day One Biopharmaceuticals and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Day One Biopharmaceuticals's current Days Sales Outstanding is 36.89, which is 14% below median its own 10-year median of 42.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Day One Biopharmaceuticals stock overvalued right now?
Day One Biopharmaceuticals (DAWN) has a current Days Sales Outstanding of 36.89. The current Days Sales Outstanding is 36.89, which is 14% below median its 10-year median of 42.73 and 46.5% below the Biotechnology industry median of 68.94. Day One Biopharmaceuticals' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Day One Biopharmaceuticals (DAWN), the current Days Sales Outstanding is 36.89 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
12GF Score
Get the complete analysis for DAWN
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DAWN has been successfully added to your 
